Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Note: Metadata referenced "Biolife Solutions," but the filing text identifies the registrant as Cryomedical Sciences, Inc.)
Reporting Period: Quarterly period ended September 28, 1997 (Nine months ended September 28, 1997).
Business Overview: The Company researches, develops, markets, and manufactures products for low-temperature medicine, primarily the AccuProbe cryosurgical systems. The Company is seeking funding to commercialize its Hypothermosol preservation solutions.
Key Financial Metrics
| Metric | Three Months Ended Sept 28, 1997 | Nine Months Ended Sept 28, 1997 | Nine Months Ended Sept 30, 1996 |
|---|---|---|---|
| Revenues | $691,948 | $2,539,258 | $4,115,906 |
| Gross Profit | $278,990 | $1,121,114 | $1,519,673 |
| Gross Margin | 40% | 44% | 37% |
| Operating Loss | $(258,884) | $(1,062,868) | $(2,758,657) |
| Net Loss | $(271,752) | $(999,543) | $(2,750,455) |
| Net Loss Per Share | $(0.01) | $(0.03) | $(0.11) |
| Cash & Equivalents | Balance Sheet Data (Sept 28, 1997 vs Dec 29, 1996) Cash: $241,967 (vs $1,769,243) Working Capital: $2,207,945 (vs $3,164,304) | ||
| Net Cash Used in Operations |
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 27% for the quarter and 38% for the nine-month period compared to the prior year. Management attributes this to a decline in AccuProbe system sales driven by a lack of formal Medicare reimbursement for urologic cryosurgery.
- Expense Reductions: Operating expenses decreased significantly due to headcount reductions and lower travel costs.
- Research & Development: Down 27% (quarter) and 25% (nine months).
- Sales & Marketing: Down 38% (quarter) and 57% (nine months).
- General & Administrative: Down 40% (quarter) and 56% (nine months).
- Improved Efficiency: Despite lower revenues, operating expenses as a percentage of revenue decreased from 104% to 86% for the nine-month period.
- Liquidity Position: Cash and short-term investments dropped from $1.88 million to $352,117 due to operating losses and capital expenditures of $275,030 (including $135,426 in consignment/loaner systems).
Outlook, Risks, and Contingencies
- Reimbursement Risk: Sales are heavily constrained by the absence of national Medicare coverage guidelines for urological cryosurgery. The Health Care Financing Administration (HCFA) is considering a non-coverage policy pending a clinical study comparing cryosurgery to radiation therapies.
- Liquidity Outlook: Management believes current cash and working capital, combined with potential financing and cost-cutting, will fund operations for the next 12 months. However, the Company expects to pursue short-term financing and possibly additional equity financing.
- Legal Contingencies:
- EndoCare Litigation: The Company is suing EndoCare, Inc. and former VP Dr. ZhoaHua Chang for trade secret misappropriation and breach of contract. The Company seeks $30 million in damages. A preliminary injunction against Dr. Chang was modified to allow limited consulting on non-cryosurgical projects. Proceedings are stayed pending mediation.
- Concept Group Litigation: Vendor Concept Group, Inc. sued the Company for approximately $3 million, alleging patent theft and fraudulent ordering schemes. The Company denies liability and intends to defend vigorously.
Investor Verification Checklist
- Verify the status of the HCFA/Medicare reimbursement decision for urological cryosurgery and its potential impact on future sales.
- Confirm the Company's ability to secure additional funding given the significant cash burn and reduced working capital.
- Monitor the outcome of the mediation in the EndoCare lawsuit and the defense strategy against the Concept Group lawsuit.
- Assess the progress of the Hypothermosol preservation solution commercialization efforts.